Madrigal Pharmaceuticals' (MDGL) "Market Outperform" Rating

JMP Securities reissued their market outperform rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a report published on Friday, Benzinga reports. They currently have a $347.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on MDGL. StockNews.com upgraded Madrigal Pharmaceuticals to a sell rating […]

Related Keywords

United States , Roberte Waltermire , Piper Sandler , Blackrock Inc , Madrigal Pharmaceuticals Company Profile , Madrigal Pharmaceuticals Inc , Avoro Capital Advisors , Madrigal Pharmaceuticals Price Performance , Madrigal Pharmaceuticals , News Ratings For Madrigal Pharmaceuticals Daily , Vanguard Group Inc , Analyst Recommendations For Madrigal Pharmaceuticals , Free Report , Moderate Buy , Advisors Lp Baker , Capital Advisors , State Street Corp , Street Corp , Get Free Report , Madrigal Pharmaceuticals Daily , Nasdaq Mdgl , Mdgl , Medical , 87162t20 , Reiterated Rating , Jmp Securities ,